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ABSTRACT

We are studying reactions of cisplatin derivatives, which differ in both size and
shape, with various amino acids. When reaction with DNA occurs, apoptosis is
observed, ideally leading to termination of the cancer. Due to the affinity of cisplatin for
sulfur-containing amino acids, reaction with proteins may occur prior to access to the
DNA, producing a large array of products, which could potentially be toxic to the human
body. Both the size and shape of the platinum complexes often affect the reactions with
protein targets more so than with DNA targets. By performing reactions of specific
amino acids targets with our cisplatin derivatives, we attempt to understand the factors
that influence the targeting of these specific amino acids. In this study, cisplatin
derivatives have been reacted with the amino acids histidine, cysteine, and methionine,
and the reactions have been monitored by NMR spectroscopy, and rate constants
calculated using DYNAFIT. It has been seen that adding bulk to the ligands of our
platinum compounds has little to no effect on the reaction with histidine compared with
methionine and cysteine targets. Thus, sufficient bulk may increase the relative number
of histidine adducts compared with methionine or cysteine adducts, consequently
decreasing the toxic side effects experienced by users of the drug.

Keywords: Cisplatin, Histidine, Cysteine, Methionine, Anticancer, Nuclear Magnetic
Resonance
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CHAPTER 1

INTRODUCTION

Cancer is something that affects every person in the world in some way, shape, or
form. Whether young or old, gay or straight, man or woman, almost every person knows
someone who has, had, or will have cancer. In 2014 alone, it is estimated that 585,720
cancer-related deaths will occur in the United States, nearly 15,000 of which are expected
to be due to ovarian cancer [1]. While many anticancer drugs have been developed for a
myriad of different cancers, one commonly used chemotherapeutic in combatting ovarian
cancer is cisplatin, which is also used to fight testicular, lung, bladder, and other cancers
[2].
Cisplatin, or cis-diaminedichloroplatinum(II), was first discovered to have
anticancer activity by the Rosenberg lab at Michigan State University in 1965 [3]. This
discovery was entirely on accident as the lab was experimenting with the effect of a
generated electric field, using platinum electrodes, on the growth and division of E. coli
cells [3]. During this experiment, it was observed that the E. coli cells were growing, but
the cells were not dividing. This eventually led to the hypothesis that this inhibition was
due to the products of the platinum electrode hydrolysis [3]. The lab then discovered that
several different products were being produced by the platinum electrode hydrolysis
which could be responsible for the inhibition of the cell division [3].
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Following this, Rosenberg began to test the ability of the platinum compounds to
eliminate or reduce implanted solid Sarcoma-180 tumors in mice [3]. The results of these
assays indicated two things: one, that platinum(II) complexes exhibited the most ability
to reduce the mass of the cancerous tumors, and second, that the observed biological
effects were stereospecific [3]. These platinum(II) complexes can be found in both the
cis- and trans- isomeric forms. Complexes which exhibit anticancer activity are in the
cis- isomeric form; those in the trans- form are largely anticancer inactive. Thus
cisplatin, cis-[PtII(NH3)2Cl2], was the platinum electrode hydrolysis product which was
responsible for the anticancer activity and the first platinum-containing anticancer drug to
become FDA approved – which occurred in 1971 [3]. Transplatin, trans-[PtII(NH3)2Cl2],
was discovered to be anticancer inactive.

Figure 1.1. Structure of cisplatin.

Figure 1.2. Structure of transplatin.
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Unfortunately, cisplatin showed some severe dose-limiting side effects including
nephrotoxicity – severe kidney damage – to the patient and this spawned the search for
other platinum-based anticancer drugs which were just as effective as cisplatin in terms
of combatting cancer, but caused far fewer side effects. Following first-generation
cisplatin, second-generation carboplatin was developed, and since that time there have
been thousands of platinum drug derivatives created and tested for their anticancer
activity in the hopes of creating a better drug [4]. From all of these options, only thirdgeneration oxaliplatin along with carboplatin and cisplatin, have been approved for
international marketing [5], though others, such as phenanthriplatin, have shown promise
in clinical trials. In order to become FDA approved, that drug must show at least one
advantage over cisplatin. Both carboplatin, FDA approved in 1989 [6], and oxaliplatin,
FDA approved in 2002 [5], are effective against cancer cell lines that are cisplatinresistant. Carboplatin is predominately used in the combat of ovarian cancer [5] but is
also used to treat non-small cell lung and other cancers [6], while oxaliplatin is more
commonly used in cases of colorectal cancer [5].

Figure 1.3. Structure of carboplatin.

Figure 1.4. Structure of oxaliplatin.
3

Regrettably, both carboplatin and oxaliplatin present severe dose-limiting side
effects as well, though they are different from those of cisplatin. While nephrotoxicity
was one of the dominant side effects caused by cisplatin, carboplatin tends to cause
myelosuppression – an extreme decrease in bone marrow activity causing a reduction in
both red and white blood cells as well as platelets – and oxaliplatin is guilty of causing
neurotoxicity – interfering with the normal activity of the nervous system [5]. Thus, it
should come as no surprise that the hunt for a more effective and less toxic anticancer
drug continues today.
One of the believed causes for some of the severe side effects experienced by
cisplatin-users is the sulfur-platinum(II) binding [7]. Because sulfur is quite abundant in
the human body, present in biomolecules such as glutathione and amino acids cysteine
and methionine to name a few, there is thus a high probability for these sulfurplatinum(II) bonds to be formed. Many studies suggest that within 24 hours of cisplatin
administration, roughly between 65% and 98% of the cisplatin has been sequestered by
proteins [7]. This is unfortunate for two reasons: first, the most common way to
deactivate the platinum-drug is for it to form a protein adduct, and second, protein
adducts are most commonly formed through by sulfur-platinum(II) bonding. So, not only
does the drug become less potent because much of it is deactivated, this deactivation
through a sulfur-platinum(II) bonded protein adduct is thought to be toxic to the patient.
Though the platinum center of cisplatin has an affinity for sulfur, the anticancer
mechanism of cisplatin is dependent on the drug being able to enter the cancerous cells
and bond with the DNA; in order to do this the drug must first be uptaken into the
cancerous cell. While the uptake method of cisplatin in not entirely understood, studies
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suggest that both passive diffusion and use of CTR1 play a key role in drug uptake [4, 7,
8], neither of which can occur if the drug is protein-bound. Many of the earlier studies on
the topic of cisplatin uptake suggest that unaquated cisplatin – meaning the two chlorines
are bonded to the platinum center, shown in Figure 1.1 – passively diffuses through the
cell membrane into the tumor cell [4, 7]. More recent research has shown that cisplatin
may be actively transported into the cell via CTR1 [4, 8]. CTR1 is a transmembrane
copper transporter containing a central trimeric pore composed of histidines, methionines,
and cysteines. As previously stated, the platinum center has an affinity for sulfur, thus
making the pore of CTR1 an attractive binding option. The use of CTR1 to transport
platinum drugs into cells is evidenced by studies which have found that the deletion, or
even mutation, or the CTR1 gene causes an increase in cell resistance to cisplatin while
an overexpression of the gene causes an increase in platinum drug concentration within
the cells [4, 8]. Thus, it can be said that the cytotoxicity of cisplatin seems to be
regulated by CTR1.
Outside of the cell, the drug remains in its unaquated form due to the extremely
high concentrations of chloride ion ([Cl-] ≈ 100 mM), but once it is inside the cell the
chloride concentration is much lower ([Cl-] ≈ 4 mM) and the drug becomes aquated –
meaning that the chlorine atoms of cisplatin are displaced by water, H2O [7]. Cisplatin
first becomes mono-aquated, cis-[PtII(NH3)2(H2O)Cl]+ – where only a single chlorine is
displaced – and finally bis-aquated, cis-[PtII(NH3)2(H2O)2]2+ – both chlorines displaced
by water. This aquation process is important because once the drug becomes positively
charged it cannot leave the cell and can diffuse into the cell’s nucleus where it can bind
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with the DNA. Roughly 98% of the DNA-platinum adducts are formed from the monoaquated species, though there are other DNA-platinum adducts that can form as well [7].

Figure 1.5. Homotrimeric pore of the transmembrane CTR1 where M indicates
methionine, C indicates cysteine, and H indicates histidine [8].

Cisplatin is anticancer active due to the way that the aquated forms interact with
cancerous cell DNA. As Figure 1.6 indicates, there are several ways that cisplatin can
bind with the DNA in order to damage it: both inter- and intra-strand crosslinks, as well
as a protein-DNA crosslink. Once inside the nucleus, the central platinum atom binds
with the N7 atoms of the DNA bases guanine and adenine, though guanine is preferred [4,
9]. The most common DNA adduct produced is that of the intra-strand crosslink, either
the 1,2, which typically occurs between two adjacent guanines, or the 1,3, which binds to
guanines in a GXG sequence where X is another DNA base. Adjacent guanine residues
are preferred because this region is the most electronegative of the double-stranded DNA,
and thus the positively charged aquated product targets this region [9]. While adjacent
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guanines residues are preferred, an adenine residue in conjunction with a guanine residue
can also produce crosslinks. But it should be noted that all DNA adducts, not solely the
intra-strand crosslinks, play a role in the drug’s toxicity [4, 9].

Figure 1.6. Visual depiction of possible crosslinks that can be produced by aquated
species [10].
7

Ideally, these crosslinks kink the DNA in such a way that the repair proteins
cannot fix the DNA and cell death is triggered. The 1,2-intrastrand crosslink in particular
distorts the DNA in such a way that the DNA’s minor groove is exposed, revealing the
area where several different classes of proteins can bind, such as high-mobility group
(HMG) box, repair and transcription proteins [4]. The HMG proteins are preferential
toward platinum-guanine adducts, and specific proteins such as HMGB1 bind to the
platinum-guanine adduct in order to protect it from repair proteins [4]. This DNA
damage induces cell cycle arrest which then prompts apoptosis – cell death. It is the
inability of transplatin to form these types of crosslinks which accounts for its anticancer
inactivity.
While the main targets of these platinum-containing drugs are DNA, much of the
drug is sequestered by proteins and other biomolecules before it reaches the cancer cell
DNA. Since these proteins are found in places such as the blood it is extremely
important to understand these reactions and how they change as the drug derivative
changes. The focus of our research is on understanding how the reactions between
cisplatin derivatives and certain amino acids found within proteins change depending on
the size and shape of the attached ligands. In other words, we want to understand how
much bulk can be added to these drugs before severe retardation of the reaction rate is
observed. In this research, we will specifically focus on the acetylated forms of three
amino acids – cysteine (Figure 1.8), methionine (Figure 1.7), and histidine (Figure 1.9) –
and how added bulk on both the leaving and carrier ligands of the drug will affect the
reaction rates with these amino acids. We will also be looking at which products are
formed during each of these reactions.
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Figure 1.7. Structure of N-AcMet

Figure 1.8. Structure of N-AcCys

Figure 1.9. Structure of N-AcHis

There are several reasons these three amino acids were chosen for investigation
into their reactions with platinum drug derivatives. First, as stated previously, platinum
drug reaction with sulfur-containing biomolecules is believed to be one of the causes of
toxicity; both methionine and cysteine are sulfur containing amino acids found in many
proteins and are both responsible for sequestration of platinum-containing anticancer
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drugs. Therefore it is imperative to study the products formed in these reactions. In
addition, it is necessary to investigate the reaction rates of platinum-containing drugs
with these three amino acids because they compose the trimeric pore of CTR1, which
partially regulates drug uptake into the cancerous cells. Therefore, we need to evaluate
whether or not our drug derivatives still possess a reaction rate fast enough to allow the
drug to be transported into the cancer cells.

Figure 1.10. Visual representation for the split between bulkier carrier and leaving
ligands, and structures for the four compounds used in this research.
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In this case we have chosen to use four different cisplatin drug derivatives. Two
derivatives have nitrate leaving ligands, and two have oxalate leaving ligands; one of
those with the nitrate leaving ligand has an en carrier ligand and the other an Me4en
carrier ligand, and the same trend holds for those with the oxalate leaving ligand. A
visual representation, including structures for each of the cisplatin derivatives used in this
research, of this can be found in Figure 1.7. We expect that as the bulk of the platinum
compound increases, the reaction rate with respect to one amino acid will slow down. In
addition, we expect that as the leaving ligand is changed from a non-chelating ligand
(nitrate) to a chelating ligand (oxalate), the reaction rate with respect to one amino acid
will decrease; this is due to the chelate effect. First of all, a chelate is any ligand that
binds to the metal center through more than one atom. So in this case, en, Me4en, and
oxalate are all chelates. Secondly, the chelate effect is the concept that chelated
compounds are more stable than non-chelated compounds and thus the greater the
number of chelates, the more thermodynamically stable the compound will be.
What we have found is, for the most part, what we expected. In terms of
methionine, adding bulk to the carrier ligand of the compound greatly reduced the rate of
reaction; this holds for cysteine as well. What was interesting was our finding in relation
to histidine and rate of reaction as bulk is increased on the carrier ligand and a chelating
leaving ligand is used. In terms of the nitrate leaving ligands, there was negligible
difference between the reaction rates with histidine as we varied the carrier ligand [11].
But as we replace the nitrate leaving ligand with oxalate, while keeping the carrier ligand
the same, the reaction rate with histidine is so retarded that product formation is
negligible even after 14 months of reaction time. This indicates that increasing the bulk
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of the carrier ligands would reduce the rate of reaction with both cysteine and
methionine, while the reaction with histidine would not change. In addition, we now
know that by adding a chelating leaving ligand to our platinum drug derivative, the
reaction rate with histidine retards so greatly that reaction is considered not to have
occurred.
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CHAPTER 2

MATERIALS AND METHODS

The following chemicals were purchased for use in syntheses performed for this research:

Deuterium oxide (D2O) (Aldrich, 99.9 atom % D), Potassium tetrachloroplatinate(II)
(Aldrich, 98%), Ethylenediamine (Acros, p.a.), N,N,N’,N’-tetramethylethylenediamine
(Acros, 99%), Oxalic acid (Acros, anhydrous p.a.), Silver nitrate (Sigma-Aldrich,
≥99.0%), Potassium iodide (Sigma-Aldrich, 99+%, A.C.S. reagent), Acetone (SigmaAlrich, Histological grade, ≥99.5%), Methanol (Sigma-Aldrich, HPLC grade, ≥99.9%),
dichloro(ethylenediamine)platinum(II) (Alrich, 99%), N-Acetyl-L-cysteine (Acros, 98%),
N(alpha)-Acetyl-L-histidine monohydrate (Acros, 99+%), N-Acetyl-L-methionine (Fluka
Analytical, ≥98.5%).

All synthesis products were checked for purity using a JEOL Eclipse 500 MHz nuclear
magnetic resonance (NMR) spectrometer and collecting 1H NMR spectra. In each case,
deuterium oxide (D2O) was used as a standard reference. The following syntheses were
commonly used:

13

Synthesis of diiodo(ethylenediamine)platinum(II):
430 mg of potassium tetrachloroplatinate(II) was combined with 1315 mg of potassium
iodide (excess) in approximately 5 mL of deionized water. After approximately 3 hours,
the reaction mixture was syringe filtered into a round bottom flask and 167 μL of
ethylenediamine ligand was added dropwise and another 5 mL of deionized water added.
The reaction was allowed to stir overnight and a yellow mustard colored precipitate was
noted. The solution was vacuum filtered in order to collect the precipitate. The solid was
washed once with deionized water, then ethanol, and then diethyl ether. Once dry, the
solid was collected. Yield = 486.2 mg.

Figure 2.1. Synthesis of Pt(en) diiodide
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Synthesis of diiodo(N, N, N’, N’-tetramethylethylenediamine)platinum(II):
464.5 mg of potassium tetrachloroplatinate(II) was combined with 1303 mg of potassium
iodide (excess) in approximately 5 mL of deionized water. After approximately 3 hours,
the reaction mixture was syringe filtered into a round bottom flask and 375 μL of
(N,N,N’,N’-tetramethylethylenediamine) ligand was added dropwise and another 5 mL of
deionized water was added. The reaction was allowed to stir overnight and a brown mudcolored precipitate was noted. The solution was vacuum filtered in order to collect the
precipitate. The solid was washed once with deionized water, then ethanol, and then
diethyl ether. Once dry, the solid was collected. Yield = 534.6 mg.

Figure 2.2. Synthesis of Pt(Me4en) diiodide
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Synthesis of (N, N’-ethylenediamine)platinum(II) nitrate:
103.0 mg of previously synthesized diiodo(N,N’-ethylenediamine)platinum(II) was
added to an aluminum foil-covered Erlenmeyer flask containing approximately 150 mL
of acetone, which was swirled until the platinum compound was completely dissolved.
Then, 69.2 mg of silver nitrate was added to solution and the reaction was allowed to stir
overnight. Gravity filtration was then performed in order to remove the precipitate and
the filtrate was collected in a round bottom flask. The solvent was then rotary evaporated
off and the remaining solid product collected and weighed. Yield = 66.9 mg.

Figure 2.3. Synthesis of Pt(en) Nitrate
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Synthesis of (N, N, N’, N’-tetramethylethylenediamine)platinum(II) nitrate:
25.5 mg of previously synthesized diiodo(N,N,N’,N’tetramethylethylenediamine)platinum(II) was added to an aluminum foil-covered
Erlenmeyer flask containing approximately 15 mL of acetone, which was swirled until
the platinum compound was completely dissolved. Then, 15.3 mg of silver nitrate was
added to solution and the reaction was allowed to stir overnight. Gravity filtration was
then performed in order to remove the precipitate and the filtrate was collected in a round
bottom flask. The solvent was then rotary evaporated off and the remaining solid product
collected and weighed. Yield = 8.9 mg.

Figure 2.4. Synthesis of Pt(Me4en) Nitrate
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Synthesis of Silver Oxalate:
500.2 mg of silver nitrate was added to aluminum foil-covered Erlenmeyer flask
containing approximately 25 mL of deionized water. Next, 149.9 g of oxalic acid was
added to the flask and was allowed to stir overnight and a white precipitate was noted.
Gravity filtration was then performed in order to collect the white solid precipitate. Once
dried, the precipitate was collected and weighed and then stored in the dark.
Yield = 376.1 mg.

Figure 2.5. Synthesis of silver oxalate
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Synthesis of (N, N’-ethylenediamine)platinum(II) oxalate:
35.1 mg of dichloro(ethylenediamine)platinum(II) was placed in an aluminum foilcovered Erlenmeyer flask in 45 mL of deionized water. 33.0 mg of previously
synthesized silver oxalate was added and the reaction was allowed to stir in the dark over
night. Gravity filtration was then performed in order to remove excess solid and the
filtrate collected in a round bottom flask. The round bottom was then placed on a rotary
evaporator, in order to remove the solvent, and in a 45°C water bath, in order to ensure
ligand coordination. The solid product was then weighed and stored. Yield = 25.6 mg.

Figure 2.6. Synthesis of Pt(en)(ox)
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Synthesis of dichloro(N, N, N’, N’-tetramethylethylenediamine)platinum(II):
Solution A: 5 mL of methanol was mixed with 85 μL of (N,N,N’,N’tetramethylethylenediamine) ligand in a 10 mL glass vial.
Solution B: 5 mL of deionized water and 167.5 mg of potassium tetrachloroplatinate (II)
were mixed in a 10 mL glass vial.
Next, solution A was added DROPWISE to solution B and there was a noted color change
from yellow to orange. The reaction was allowed to stir overnight and a precipitate was
formed. The solution was then transferred to a round bottom flask, and a rotary
evaporator was used to removed the solvent. The solid product was then collected and
weighed. Yield = 45.1 mg.

Figure 2.7. Synthesis of Pt(Me4en) dichloride
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Synthesis of (N, N, N’, N’-tetramethylethylenediamine)platinum(II) oxalate:
39.9 mg of previously synthesized dichloro(N,N,N’,N’tetramethylethylenediamine)platinum(II) was placed a 40 mL amber vial with
approximately 40 mL of deionized water. 30.4 mg of silver oxalate was then added and
the reaction was allowed to stir over night. The solution was then gravity filtered in order
to remove any excess solid and the filtrate was collected in a round bottom flask. The
round bottom was then placed on a rotary evaporator, in order to remove the solvent, and
in a 40°C water bath, in order to ensure ligand coordination. The solid product was then
weighed and stored. Yield = 20.3 mg.

Figure 2.8. Synthesis of Pt(Me4en)(ox)
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All reactions were monitored using a JEOL Eclipse 500 MHz nuclear magnetic resonance
(NMR) spectrometer and collecting 1H NMR spectra at selected intervals of time, either
manually or via use of a kinetics module.

The following reactions were performed in the specified concentrations at the adjusted
pH and then monitored via 1H NMR to determine reaction kinetics and observe products:

Pt(en)(NO3)2 + N-AcMet:
1:1 Pt:N-AcMet molar ratio – 10 mM stock solutions of Pt(en)(NO3)2, N-AcMet, and
sodium nitrate were prepared in D2O. 100 μL of Pt(en)(NO3)2 stock solution, 100 μL of
N-AcMet stock solution, 100 μL of sodium nitrate stock solution, and 700 μL of D2O
were combined in a clean NMR tube and the pH was adjusted to 4.

Pt(en)(NO3)2 + N-AcHis:
1:1 Pt:N-AcHis molar ratio – 10 mM stock solutions of Pt(en)(NO3)2, N-AcHis, and
sodium nitrate were prepared in D2O. 100 μL of Pt(en)(NO3)2 stock solution, 100 μL of
N-AcHis, 50 μL of sodium nitrate stock solution, and 200 μL of D2O were combined in a
clean NMR tube. The pH was adjusted to 4.
1:2 Pt:N-AcHis molar ratio – 10 mM stock solutions of Pt(en)(NO3)2, N-AcHis, and
sodium nitrate were prepared in D2O. 100 μL of Pt(en)(NO3)2 stock solution, 200 μL of
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N-AcHis, 50 μL of sodium nitrate stock solution, and 100 μL of D2O were combined in a
clean NMR tube. The pH was adjusted to 4.
30:5 Pt:N-AcHis molar ratio – 40 mM stock solutions of Pt(en)(NO3)2, N-AcHis, and
sodium nitrate were prepared in D2O. 450 μL of Pt(en)(NO3)2 stock solution, 75 μL of
N-AcHis, and 75 μL of sodium nitrate stock solution were combined in a clean NMR
tube. The pH was adjusted to 4.

Pt(Me4en)(NO3)2 + N-AcHis:
30:5 Pt:N-AcHis molar ratio – 40 mM stock solutions of Pt(Me4en)(NO3)2, N-AcHis, and
sodium nitrate were prepared in D2O. 450 μL of Pt(Me4en)(NO3)2 stock solution, 75 μL
of N-AcHis, and 75 μL of sodium nitrate stock solution were combined in a clean NMR
tube. The pH was adjusted to 4.
1:1 Pt:N-AcHis molar ratio – 5 mM stock solutions of Pt(Me4en)(NO3)2 and N-AcHis
were prepared in D2O. 300 μL of Pt(Me4en)(NO3)2 stock solution and 300 μL of NAcHis stock solution were combined in an NMR tube.

Pt(en)(ox) + N-AcHis:
1:1 Pt:N-AcHis molar ratio – 5 mM stock solutions of Pt(en)(ox) and N-AcHis were
prepared in D2O. 300 μL of Pt(en)(ox) stock solution and 300 μL of N-AcHis stock
solution were combined in a clean NMR tube. The pH was adjusted to either 4 or 7 as
required for the experiment.
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Pt(en)(ox) + N-AcCys:
1:1 Pt:N-AcCys molar ratio – 5 mM stock solutions of Pt(en)(ox) and N-AcCys were
prepared in D2O. 300 μL of Pt(en)(ox) stock solution and 300 μL of N-AcCys were
combined in a clean NMR tube. The pH was adjusted to either 4 or 7 as required for the
experiment.

Pt(Me4en)(ox) + N-AcCys:
1:1 Pt:N-AcCys molar ratio – 5 mM stock solutions of Pt(Me4en)(ox) and N-AcCys were
prepared in D2O. 300 μL of Pt(Me4en)(ox) stock solution and 300 μL of N-AcCys were
combined in a clean NMR tube. The pH was adjusted to 7.

Depending on the accuracy of rate constant needed for each reaction, the rate constant
was either estimated or determined using DYNAFIT software and the collected 1H NMR
spectra.
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CHAPTER 3

RESULTS

Just Reacted

20 minutes

40 minutes

Figure 3.1. Partial 1H NMR spectra of the reaction of 1 mM Pt(en)(NO3)2, 1 mM sodium
nitrate, and 1 mM N-AcMet with a total reaction time of 60 minutes at pH 4 and 25 °C.
The peaks associated with reactant and products are indicated, and the y-axis has been
scaled to the highest peak. The x-axis is measured in ppm.
25

The unreacted N-AcMet has two prominent singlets at roughly 2.0 ppm and 2.1 ppm, and
the prominent singlet at approximately 2.45 is associated with the Pt(en)(NO3)2. Upon
product formation, there are four signals indicated in the middle spectra of Figure 3.1.
The singlet at 2.45 and the doublet between 2.4 and 2.45 ppm more than likely indicates
the formation of the [Pt(en)(N-AcMet-S,N)]+ chelate. The remaining singlet at 2.35 ppm
is associated with the hydrogens of the S-CH3 group. The rate constant for this reaction
was calculated using DYNAFIT and was determined to be 3.8 ± 0.7 M-1 s-1 [11].
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40 minutes

140 minutes

220 minutes

Figure 3.2. The downfield (left) and upfield (right) partial 1H NMR spectra of the
reaction of 30 mM Pt(en)(NO3)2 and 5 mM N-AcHis (30:5) over the time period of
approximately 4 hours at pH 4 and 25 °C. The peaks associated with reactants and
products are indicated, and the y-axis has been scaled to the highest peak. The x-axis is
measured in ppm.
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In the top left spectrum of Figure 3.2, two singlets can be seen at approximately 8.65 ppm
and 7.3 ppm – these are characteristic of unreacted N-AcHis. In the right upper hand
spectrum of Figure 3.2, the singlet at approximately 2.02 ppm indicates the acetyl group
of N-AcHis. The platinum signal has been excluded from the spectrum due to the fact
that platinum is in such high concentration that the peak does not change significantly.
After only 40 minutes of reaction time at a pH of 4, we see that product peaks have
started to evolve. All three of the indicated product signals – at roughly 8.65 ppm, 7.3
ppm, and 1.97 ppm – are indicative of the product, which in this case we believe to be a
mono-product coordinated through a Pt-N bond. The rate constant for this reaction was
calculated using DYNAFIT and was determined to be 7.2 ± 0.7 x 10-3 M-1 s-1 [11].
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20 minutes

30 minutes

160 minutes

280 minutes

Figure 3.3. The downfield (left) and upfield (right) partial 1H NMR spectra of the
reaction of 30 mM Pt(Me4en)(NO3)2 and 5 mM N-AcHis (30:5) over the time period of
approximately 4 hours at pH 4 and 25 °C. The peaks associated with reactants and
products are indicated, and the y-axis has been scaled to the highest peak. The x-axis is
measured in ppm.
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The singlet signals in the top left spectrum of Figure 3.3, seen at approximately 8.65 ppm
and 7.3 ppm, are characteristic of unreacted N-AcHis. And in the upper right spectrum of
Figure 3.3, the signal at approximately 2.02 ppm is associated with the acetyl group of NAcHis. The platinum signal has not been shown in the partial spectrum due to the fact
that platinum is in such high concentration that the peak does not change significantly
throughout the reaction. After 40 minutes of reaction time, at only a pH of 4, product
peaks have started to evolve. All three of the indicated product peaks shown in Figure
3.3 – found at 8.65 ppm, 7.3 ppm, and 2.0 ppm – are associated with the mono-product
which we believe to be a mono-product coordinated through the Pt-N bond. The rate
constant for this reaction was calculated using DYNAFIT and was determined to be 8.5 ±
0.6 x 10-3 M-1 s-1 [11].
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Just Reacted

5 Months

Figure 3.4. The downfield (left) and upfield (right) partial 1H NMR spectra of the
reaction of 5 mM Pt(en)(ox) and 5 mM N-AcHis (1:1) over the time period of
approximately 5 months at pH 7 and approximately 18 °C (room temperature). The
peaks associated with reactants are indicated, and the y-axis has been scaled to the
highest peak. The x-axis is measured in ppm.
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The prominent signals at approximately 8.2 ppm, 7.4 pppm, and 1.95 ppm indicate the
presence of unreacted N-AcHis, while the signal at approximately 2.5 ppm is
characteristic of our platinum compound – Pt(en)(ox). After 5 months of reaction time,
no significant reaction was observed. The same reaction sample was checked again via
1

H NMR after 14 months of reaction time, only to find very minimal reaction.
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0.5 Hours

49 Hours

74 Hours

145.5 Hours

Figure 3.5. Partial 1H NMR spectra of the reaction of 5 mM Pt(en)(ox) and 5 mM NAcCys over the time period of 6 days at pH 7 and approximately 18 °C (room
temperature). The peaks associated with reactants, products, and free ligand are indicated,
and the y-axis has been scaled to the highest peak. The x-axis is measured in ppm.
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The prominent signal at approximately 1.95 ppm is characteristic of N-AcCys, and the
singlet at roughly 2.5 ppm is associated with our platinum compound – Pt(en)(ox). After
49 hours of reaction time we begin to see product and free en ligand. The singlet peak at
roughly 3.35 ppm indicates our free en ligand, and there are three prominent product
peaks labeled in Figure 3.5. The singlet peak at approximately 2.65 ppm and the doublet
at roughly 2.2 ppm more than likely indicate a bis-chelate product, with two chelated
cysteines to one platinum center coordinate through Pt-S and Pt-N bonds. The rate
constant for this reaction was estimated using the integration function of the JEOL Delta
program and DYNAFIT and was determined to be approximately 2×10-4 M-1 s-1.
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Just Reacted

8.5 Days

21 Days

36 Days

Figure 3.6. Partial 1H NMR spectra of the reaction of 5 mM Pt(en)(ox) and 5 mM NAcCys over the time period of 36 days at pH 7 and approximately 18 °C (room
temperature). The peaks associated with reactants, products, and free ligand are
indicated, and the y-axis has been scaled to the highest peak. The x-axis is measured in
ppm.
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The signal at roughly 2.0 ppm is characteristic of N-AcCys, while the two prominent
singlet peaks indicated in the topmost spectrum of Figure 3.6, located at approximately
3.0 ppm and 2.8 ppm, are indicative of Pt(Me4en)(ox). After 8.5 days of reaction time we
start to see some product formation and free Me4en ligand. The signal at roughly 2.85
ppm, in conjunction with a singlet noted at approximately 3.6 ppm which is not shown,
we known that there is free Me4en ligand in solution [12]. The doublet shown at
approximately 2.0 ppm and the singlet at roughly 2.05 ppm indicate a bis-chelated
product of 2 cysteines to one platinum center, coordinate through Pt-S and Pt-N bonds.
The rate constant for this reaction was estimated using the integration function of the
JEOL Delta program and DYNAFIT and was determined to be approximately 6.5×10-5
M-1 s-1.
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CHAPTER 4

DISCUSSION

We have found that Pt(en)(NO3)2 in its reaction with N-AcMet predominately
forms a [Pt(en)(N-AcMet-S,N)]+ chelate. In previous research, it has been shown that
this reaction can produce three possible products: [Pt(en)(N-AcMet-S,N)]-, [Pt(en)(NAcMet-O,S)]+, and/or [Pt(en)(N-AcMet-S)2] [12]. The first product is likely the more
thermodynamically favored in the reaction of 1:1 molar ratio Pt(en)(NO3)2 and N-AcMet,
which can be found in Figure 3.1, due to the 1:1 ratio. The bis-product in this case is not
favorable in a 1:1 reaction, but when there is an excess of N-AcMet in 2:1 or greater [12].
The formation of our chelated product is evidenced by the formation of the doublet at
approximately 2.3 ppm indicating the hydrogens of the en ligand, and the singlet at 2.45
from the acetyl hydrogens. There may also be evidence of a 1:1 N-AcMet:Pt monoproduct, but due to the chelate effect and thermodynamic favorability, the chelated
product results from this. We believe that the first step in the reaction mechanism is the
formation of the [Pt(en)(N-AcMet-S)(H2O)] product, which is the slowest reaction step;
the mono-chelated product, [Pt(en)(N-AcMet-S,N)]-, is then quickly formed. Thus, the
reaction rate for this chelation reaction is actually determined by the first step, the
formation of the mono-product, and was determined to be 3.8 ± 0.7 M-1 s-1 [11]. In
addition it should be noted that upon bulk addition to the carrier ligand (from en to
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Me4en), the reaction rate was significantly retarded [11]. The ratio of ken/kMe4en was
found to be 16, indicating that the reaction rate was slowed by a factor of 16 as sufficient
bulk was added to the platinum compound [11].
In the reaction of N-AcHis with Pt(en)(NO3)2 it was found that the dominant
product of the reaction was a 1:1 N-AcHis:Pt mono-product coordinated through a Pt-N
bond. This was still the observed product even when the platinum was in extreme excess
in the 30:5 Pt:N-AcHis molar ratio observed in Figure 3.2. We believe that one reason
for the observed sluggishness of the reaction is due to the fact that displacement of the
NO3 ligand by a N is less favorable than the displacement by a S, and thus slower. In
addition, the formation of the mono-product and lack of chelated product may be due to
the large planar ring of N-AcHis, making chelation difficult. This mono-product is
evidenced predominately through the production of three product peaks – at roughly 8.65
ppm, 7.3 ppm, and 1.97 ppm – as can be seen in Figure 3.2. The singlet at 1.97 ppm is
indicative of the acetyl hydrogen of N-AcHis, and the other two indicated product
singlets represent the imidazole hydrogens. The slight chemical shift between the
unreacted N-AcHis singlets and the two product singlets at roughly 8.65 ppm and 7.3
ppm is characteristic of a product coordinated through the imidazole nitrogen. In order to
verify this we increased the sample from its pH of 4, to 5, 6, and finally 7 in order to
determine whether it was coordinated through the imidazole nitrogen. Due to the lack of
peak shift as the pH changed, we know that the Pt center is coordinated through the
imidazole nitrogen in this product. In addition, a rate constant for the reaction was
calculated using DYNAFIT and was found to be 7.2 ± 0.7 x 10-3 M-1 s-1 [11].
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Following this, we developed another platinum drug derivative with a bulkier
carrier ligand than the previous experiment, Me4en, in order to determine how the
reaction rate changed. From this reaction of Pt(Me4en)(NO3)2 and N-AcHis, we can see
that the preferred product is again a 1:1 N-AcHis:Pt mono-product coordinated through
the imidazole nitrogen. As indicated in Figure 3.3, we can see that again there are three
prevalent product peaks formed at 8.65 ppm, 7.3 ppm, and 2.0 ppm which indicate the
previously described product. In this case, since we increased the bulk of the carrier
ligand by adding four methyl groups, we hypothesized that the reaction rate would be
retarded due to the increased steric hindrance. Surprisingly, we found that there was
negligible difference between the rate of the previous reaction, 7.2 ± 0.7 x 10-3 M-1 s-1,
and this rate of reaction, which was found to be 8.5 ± 0.6 x 10-3 M-1 s-1 [11]. While these
rates may appear different, the ratio of ken/kMe4en in this case is 1, thus revealing that there
is negligible difference between the rates of the two reactions and that bulk addition has
no effect with N-AcHis [11].
Following this, we wished to investigate the change in the rate of reaction as we
increased the bulk of the platinum compound leaving ligand from nitrate to oxalate. In
this case we first wanted to observe the 1:1 reaction of N-AcHis and Pt(en)(ox) at pH7
and room temperature (18 °C). After roughly 2 weeks of reaction time, there was still no
product formation, so we opted to just let the reaction run, checking it periodically for
reaction. Finally after about 5 months, a miniscule amount of product was observed, and
even after 14 months of reaction there was only a small amount of product formation.
The partial 1H NMR spectra from this reaction can be seen in Figure 3.4 and indicate this
lack of product formation. Originally, we also desired to observe the 1:1 reaction of N-
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AcHis and Pt(Me4en)(ox), but once we realized how slow the previous reaction had
proceeded, we knew that it would be an incredibly time-consuming process to try to
observe this reaction as well. In addition, we deemed these reactions too slow to have
any biological relevance due to the likelihood that the platinum drug will have reacted
with something else well before this reaction would take place.
Upon observing the reaction of N-AcCys and Pt(en)(ox), which we knew would
be much faster than that of the N-AcHis reaction, the dominant product was found to be a
2:1 N-AcCys:Pt bis-chelate of [Pt(N-AcCys-S,N)2] even when the original reaction
mixture was 1:1. This is further supported by the findings that selenomethionine
(SeMet), a nonstandard amino acid, was found to form a bis-chelated product [Pt(SeMetSe,N)2] [13]. Thus it seems logical to follow that both N-AcMet and N-AcCys are able to
form a bis-chelated product, and thus [Pt(N-AcCys-S,N)2] is a likely product of the
reaction of N-AcCys and Pt(en)(ox). As seen in Figure 3.5, the singlet at roughly 2.65
ppm and the doublet at 2.2 ppm indicate the formation of this product. The singlet is
associated with the N-AcCys acetyl group and the doublet corresponds to the other
protons of the N-AcCys portion of the product. This bis-chelate product is further
confirmed by the presence of free en ligand in solution, which indicates that the carrier
ligand has been knocked off of the platinum and has been replaced. The removal of the
chelated oxalate carrier ligand and the following formation of the bis-chelate product is
thermodynamically favorable and thus is very probable product; this phenomenon can be
explained by examining the proposed reaction mechanism. The reaction of the first
cysteine is very slow, but upon reaction with cysteine a S-Pt bond is formed and the
chelation of the oxalate is broken, leaving a mono-dentate oxygen behind. This allows
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for the reaction of the second cysteine to take place quickly, forming another Pt-S bond,
because the mono-dentate oxygen is not as stable as the chelated oxalate and thus is
easily replaced. It should be noted that we believe the reaction of a second cysteine
occurs more quickly than the S,N-chlelation seen in previous reactions due to the
preference of S over N by Pt. Once two cysteines are coordinated to the platinum center,
the chelated en ligand is replaced with two chelated cysteines; this is favorable because
one chelate is being replaced by two chelates. In addition, we found that this 1:1 reaction
of Pt(en)(ox) and N-AcCys takes approximately 6 days to reach completion and the
estimated rate of reaction is roughly 2×10-4 M-1 s-1.
In order to understand how this reaction rate is affected by bulk addition to the
carrier ligand, the 1:1 reaction of N-AcCys and Pt(Me4en)(ox) at pH 7 and 18 °C was
observed. Upon product formation, we see a doublet at approximately 2.0 ppm and
singlets at roughly 2.65 ppm and 2.05 ppm, which are again indicative of our bis-chelate
product [Pt(N-AcCys-S,N)2]. In this case, the reaction took approximately 36 days to
reach completion and the rate was found to be 6.5×10-5 M-1 s-1. From the ratio of
ken/kMe4en, found to be approximately 3, we see that the reaction of the Me4en compound
is roughly 3-fold slower with N-AcHis than is the en compound.
It is interesting that in the case of N-AcHis, the addition of substantial bulk to the
carrier ligand of the platinum compound does not affect the rate of reaction, but in the
cases of both N-AcMet and N-AcCys the reaction is significantly affected by bulk
addition. This is an extremely substantial finding because it suggests that by adding
sufficient bulk to the platinum compound the preferred protein target could potentially be
changed from methionine or cysteine, both sulfur-containing targets, to histidine, a non-
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sulfur-containing target, or possibly another biomolecule. These results could have major
implications in reducing toxic side effects for the patient as well as increasing anticancer
effectiveness.
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